Results from a phase 3 study of Opdivo for unresectable hepatocellular carcinoma revealed that the drug showed a trend toward improvement in overall survival but did not meet significance for its primary endpoint, according to a press release from Bristol-Myers Squibb.
The phase 3 CheckMate-459 included patients randomly assigned to receive either Opdivo (nivolumab, Bristol-Myers Squibb) or Nexavar (sorafenib, Bayer) as first-line treatment for unresectable HCC.
“We are encouraged by the promising efficacy and safety trends seen with Opdivo in CheckMate-459, especially as HCC is a

Source link